PET Scans in Patients With Diffuse Large B-Cell Lymphoma Receiving Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone

NACompletedINTERVENTIONAL
Enrollment

156

Participants

Timeline

Start Date

September 30, 2007

Primary Completion Date

September 30, 2012

Study Completion Date

January 31, 2016

Conditions
Lymphoma
Interventions
BIOLOGICAL

rituximab

375 mg/m2 i.v. per cycle

DRUG

cyclophosphamide

750 mg/m2 i.v. per cycle

DRUG

doxorubicin hydrochloride

50 mg/m2 i.v. per cycle

DRUG

prednisone

100 mg/day p.o. per cycle

DRUG

vincristine sulfate

1.4 mg/m2 (max. 2.0 mg) i.v. per cycle

PROCEDURE

positron emission tomography

PET Scan during treatment

Trial Locations (19)

3600

Regionalspital, Thun

20141

European Institute of Oncology, Milan

CH-5001

Hirslanden Klinik Aarau, Aarau

Kantonspital Aarau, Aarau

CH-5404

Kantonsspital Baden, Baden

Praxis Dr. Streit, Baden

CH-4016

Saint Claraspital AG, Basel

CH-4031

Universitaetsspital-Basel, Basel

CH-6500

Oncology Institute of Southern Switzerland, Bellinzona

CH-3010

Inselspital Bern, Bern

CH-4101

Kantonsspital Bruderholz, Bruderholz

CH-7000

Kantonsspital Graubuenden, Chur

CH-1211

Hopital Cantonal Universitaire de Geneve, Geneva

CH-4410

Kantonsspital Liestal, Liestal

CH-4600

Kantonsspital Olten, Olten

CH-4310

Praxis Dr. Beretta, Rheinfelden

CH-9007

Kantonsspital - St. Gallen, Sankt Gallen

CH-8400

Kantonsspital Winterthur, Winterthur

CH-8091

UniversitaetsSpital Zuerich, Zurich

All Listed Sponsors
lead

Swiss Cancer Institute

OTHER

NCT00544219 - PET Scans in Patients With Diffuse Large B-Cell Lymphoma Receiving Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone | Biotech Hunter | Biotech Hunter